本文系统性回顾了近十几年来,从五种资料库中收集的14篇基于大麻类的药物(THC和CBD)治疗几种常见精神障碍的随机对照研究文章。结果认为这类药物虽有一定改善精神症状的作用,但现有的研究样本数较小,还应扩大样本进一步研究。 We collect 14 RCTs articles from five databases about cannabis-related drugs (THC and CBD) and systematic review of the therapeutic effect of some psychiatric disorders in the past decade or so. The results suggest that there are some effects, but further observation is needed by enlarging the sample size.
系统收集了过去10几年间用英语和德语发表的专业文章。资料检索来源于5个数据库,分别是:PsycINFO,Medline,PubMed,Embase,and the Cochrane Library。涉及该领域的所有文章均采用手工方法进行收集。根据临床问题研究和观察目标,我们设计了三种详细的不同性质的收集方法:
周小东,刘知源,苏朝霞. 运用大麻制品(THC和CBD)治疗多种精神障碍的研究进展The Research Progress of Treatment of Several Mental Disorders Using Cannabis Drugs (THC and CBD)[J]. 临床医学进展, 2020, 10(02): 123-128. https://doi.org/10.12677/ACM.2020.102020
参考文献ReferencesHoch, E., et al. (2019) How Effective and Safe Is Medical Cannabis as a Treatment of Mental Disorders? A Systematic Review. European Archives of Psychiatry and Clinical Neuroscience, 269, 87-105. <br>https://doi.org/10.1007/s00406-019-00984-4韩莎莎, 张殿杭, 李丽. 大麻二酚的药理研究进展[J]. 药物资讯, 2019, 8(3): 49-55.Ahmed, A.I., van den Elsen, G.A., Colbers, A., et al. (2015) Safety, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of Delta-9-Tetrahydrocannabinol in Older Persons with Dementia. Psy-chopharmacology, 232, 2587-2595. <br>https://doi.org/10.1007/s00213-015-3889-yVan den Elsen, G.A., Ahmed, A.I., Verkes, R.J., Feuth, T., et al. (2015) Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial. The American Journal of Geriatric Psychiatry, 23, 1214-1224. <br>https://doi.org/10.1016/j.jagp.2015.07.011Van den Elsen, G.A.H., Ahmed, A.I.A., Jan Verkes, R., et al. (2015) Efficacy and Safety of Delta-9-Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Randomized Controlled Trial. Alzheimer’s Dement, 11, 469-470. <br>https://doi.org/10.1016/j.jalz.2015.06.498Allsop, D.J., Copeland, J., Lintzeris, N., Dunlop, A.J., et al. (2014) Nabiximols as an Agonist Replacement Therapy during Cannabis Withdrawal: A Randomized Clinical Trial. JAMA Psychiatry, 71, 281-291. <br>https://doi.org/10.1001/jamapsychiatry.2013.3947Levin, F.R., et al. (2011) Dronabinol for the Treatment of Cannabis Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial. Drug Alcohol Depend, 116, 142-150. <br>https://doi.org/10.1016/j.drugalcdep.2010.12.010Levin, F.R., Mariani, J.J., Pavlicova, M., et al. (2016) Dronabinol and Lofexidine for Cannabis Use Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Drug Alcohol Depend, 159, 53-60. <br>https://doi.org/10.1016/j.drugalcdep.2015.11.025Trigo, J.M., Soliman, A., Quilty, L.C., et al. (2018) Nabiximols Combined with Motivational Enhancement/Cognitive Behavioral Therapy for the Treatment of Cannabis Dependence: A Pilot Randomized Clinical Trial. PLoS ONE, 13, e0190768. <br>https://doi.org/10.1371/journal.pone.0190768Trigo, J.M., Lagzdins, D., Rehm, J., et al. (2016) Effects of Fixed or Self Titrated Dosages of Sativex on Cannabis Withdrawal and Cravings. Drug Alcohol Depend, 161, 298-306. <br>https://doi.org/10.1016/j.drugalcdep.2016.02.020Bisaga, A., Sullivan, M.A., Glass, A., et al. (2015) The Effects of Dronabinol during Detoxification and the Initiation of Treatment with Extended Release Naltrexone. Drug Alcohol Depend, 154, 38-45. <br>https://doi.org/10.1016/j.drugalcdep.2015.05.013Jicha, C.J., Lofwall, M.R., Nuzzo, P.A., et al. (2015) Safety of Oral Dronabinol during Opioid Withdrawal in Humans. Drug Alcohol Depend, 157, 179-183. <br>https://doi.org/10.1016/j.drugalcdep.2015.09.031Boggs, D.L., Surti, T., Gupta, A., et al. (2018) The Effects of Cannabidiol (CBD) on Cognition and Symptoms in Outpatients with Chronic Schizophrenia a Randomized Placebo Controlled Trial. Psychopharmacology, 235, 1923-1932. <br>https://doi.org/10.1007/s00213-018-4885-9McGuire, P., Robson, P., Cubala, W.J., et al. (2018) Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. American Journal of Psychiatry, 175, 225-231. <br>https://doi.org/10.1176/appi.ajp.2017.17030325Jetly, R., Heber, A., Fraser, G., et al. (2015) The Efficacy of Nabilone, a Synthetic Cannabinoid, in the Treatment of PTSD Associated Nightmares: A Preliminary Randomized, Dou-ble-Blind, Placebo-Controlled Cross-Over Design Study. Psychoneuroendocrinology, 51, 585-588. <br>https://doi.org/10.1016/j.psyneuen.2014.11.002Cooper, R.E., Williams, E., Seegobin, S., et al. (2017) Canna-binoids in Attention-Deficit/Hyperactivity Disorder: A Randomised-Controlled Trial. European Neuropsychopharmacology, 27, 795-808. <br>https://doi.org/10.1016/j.euroneuro.2017.05.005